Skip to main content
. 2019 Nov 12;39(23):e00261-19. doi: 10.1128/MCB.00261-19

FIG 10.

FIG 10

Knockdown of TMPO-AS1 inhibits hormone-refractory breast tumor growth in vivo. (A) Development of OHTR-derived xenograft tumors treated with siRNAs in nude mice. siControl or siTMPO-AS1 #2 was injected twice weekly into the flanks of mice inoculated with OHTR cells (siControl, n = 7; siTMPO-AS1 #2, n = 6). Tumor volumes are presented as means ± standard errors. Representative photographs of xenografted mice are shown below. (B and C) TMPO-AS1 (B) and ESR1 (C) levels in tumors treated with siControl or siTMPO-AS #2. Tumors were dissected from mice 6 weeks after the beginning of siRNA administration. (D) Immunoblot analysis for ERα and β-actin in tumors dissected from 2 distinct mice for each group treated with either siControl or siTMPO-AS #2. (E to G) mRNA levels of MCM6 (E), CDC6 (F), and MAD2L1 (G) in tumors. Data are presented as mean fold changes ± SD versus levels for siControl (n = 3). (H) Working model of TMPO-AS1 in the proliferation and progression of ER-positive breast cancer cells. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.